Dengue Vaccines Market

Dengvaxia is projected to lead at 47.8% share in 2026, followed by Paediatric as set to secure 53.7% share of age group in 2026. Increasing dengue case burden and hospitalization rates in endemic countries are expected to push government vaccine procurement for national immunization programs.